<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03154515</url>
  </required_header>
  <id_info>
    <org_study_id>5P/08</org_study_id>
    <nct_id>NCT03154515</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults</brief_title>
  <official_title>Randomised Double Blind Placebo Controlled Multicenter Study for Evaluation of Clinical Efficacy and Safety of Ingavirin 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valenta Pharm JSC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valenta Pharm JSC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Ingavirin® 90 mg once daily is effective
      and safe for the treatment of influenza and other laboratory confirmed acute respiratory
      viral infections in the course of standard therapy in patients 18-60 years old.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the
      Efficacy and Safety of Ingavirin in the Treatment of Influenza and Other Acute Viral
      Respiratory Infection. Study treatment was 5 days followed by 2 ± 1 days of follow up period.
      Thus, study participation was 7 ± 1 days (8 days max).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to resolution of fever</measure>
    <time_frame>7 ± 1 days</time_frame>
    <description>Time from the start of study treatment to resolution of fever ( t ≤ 36,9 ºС, till the end of the follow up).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to resolution / alleviation of intoxication symptoms</measure>
    <time_frame>7 ± 1 days</time_frame>
    <description>Following symptoms were recorded and rated each visit, to evaluate symptoms progress:
Dizziness, headache, chills, fever, sweating, fatigue, myalgia, pain while moving eyes, flushing, pale skin, sleep disturbances, decreased appetite, nausea, vomiting, epistaxis, cyanosis, meningeal signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution / alleviation of catarrhal symptoms</measure>
    <time_frame>7 ± 1 days</time_frame>
    <description>Following symptoms were recorded and rated each visit, to evaluate symptoms progress:
Sore throat, rhinorrhea and nasal congestion, difficulty swallowing, hoarseness, stridor, wheezing, rattling dry and wet cough, expectoration.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Through study completion, an average of 8 days</time_frame>
    <description>All adverse events recorded and analysed, to compare incidence rate with one of placebo.
Complete blood count test performed at the beginning and at the end of the study.
Vital signs taken and recorded at each visit throughout the study, usually every day for 7 ± 1 days.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">445</enrollment>
  <condition>Common Cold</condition>
  <condition>Influenza, Human</condition>
  <condition>Acute Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>Ingavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imidazolyl ethanamide pentandioic acid 90 mg once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule identical in appearance to Ingavirin capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingavirin</intervention_name>
    <arm_group_label>Ingavirin</arm_group_label>
    <other_name>Imidazolyl ethanamide pentandioic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinically diagnosed influenza, body temperature ≥ 38 ºС or other acute
             respiratory viral infection, body temperature ≥ 37 ºС, with no less than 2 symptoms of
             catarrhal and intoxication each:

               -  Intoxication symptoms: Dizziness, headache, chills, fever, sweating, fatigue,
                  myalgia, pain while moving eyes, flushing, pale skin, sleep disturbances,
                  decreased appetite, nausea, vomiting, epistaxis, cyanosis, meningeal signs.

               -  Catarrhal symptoms: Sore throat, rhinorrhea and nasal congestion, difficulty
                  swallowing, hoarseness, stridor, wheezing, rattling dry and wet cough,
                  expectoration.

          -  Laboratory confirmation of viral origin of the disease

          -  Uncomplicated influenza and other acute respiratory viral infections

          -  Interval between onset of symptoms and enrollment to the study not more than 48 hours

          -  Have read, understood and signed an informed consent form

        Exclusion Criteria:

          -  Complicated course of influenza and other acute respiratory viral infections
             (secondary bacterial infection)

          -  Pregnancy and Breastfeeding

          -  Severe decompensated or unstable medical or psychiatric conditions (any diseases or
             conditions that threaten the life of the patient or worsen the patient's prognosis)

          -  Cancer, HIV infection, tuberculosis, including those in history

          -  History of alcohol and drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekaterina Zakharova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Valenta Pharm JSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State educational institution of higher professional education &quot;Chelyabinsk State Medical Academy of Federal Agency of Health Care and Social Development&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454092</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.F. Gamaleya Scientific Research Institute of Epidemiology and Microbiology</name>
      <address>
        <city>Moscow</city>
        <zip>123098</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State budgetary health care institution novosibirsk region &quot;city clinical infectious diseases hospital no. 1&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-western State Medical University named after I.I.Mechnikov</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University named after V. I. Razumovsky</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Educational Institution of Higher Education &quot;Pacific State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Vladivostok</city>
        <zip>690002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd State Medical University</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaroslavl State Medical University</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution of Higher Professional Education &quot;Urals State Medical University&quot; of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Tract Infections</keyword>
  <keyword>Acute Respiratory Viral Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Common Cold</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

